Stifel analyst Derek Archila reiterates his Hold rating on Intercept shares after the company reported Q3 Ocaliva sales that were in-line with estimates and management raised full year sales guidance by 2%. He thinks the majority of investors are focused on whether or not obeticholic acid has an advisory committee meeting, whether it receives a priority review in NASH and the drug's potential PDUFA date in NASH, which he expects updates on within the next few weeks. He remains cautious on obeticholic acid's commercial viability in nonalcoholic steatohepatitis given unknowns that include the pricing strategy, payer requirements and real-world compliance, Archila noted.